TScan Therapeutics reported a narrowed net loss of $30.4 million for the second quarter of 2026, primarily driven by a $9.2 million reduction in R&D expenses. The company is transitioning into a pivotal clinical stage with the commencement of its Phase 3 heme malignancy trial and has validated a commercial-ready manufacturing process.
Key Highlights
- Dosed the first patient in the pivotal Phase 3 ALLOHA-2 trial of TSC-101, with topline data expected in mid-2028.
- Achieved a 90% first-pass manufacturing success rate (17/19) using an improved, automated commercial-ready process.
- Reported that 79% of patients in Phase 1 Cohort C achieved complete donor chimerism within three weeks of receiving TSC-101 infusions.
- Maintained a cash balance of $100.2 million, providing a runway into the second quarter of 2027 despite the start of term loan amortization in Q4 2026.